Trump Administration Working on More Drug Pricing Deals, Oz Says
核心洞察
The Trump administration is pursuing additional drug pricing deals with pharmaceutical companies, CMS Administrator Mehmet Oz told Bloomberg Television.
More than two dozen voluntary agreements with pharmaceutical companies have been announced so far, and Oz said more deals are in the works.
Each agreement is bespoke, but companies generally agree to lower prices charged to public programs and to launch new drugs at prices similar to other developed markets.
The Trump administration is working on additional drug pricing agreements with pharmaceutical companies, according to Centers for Medicare and Medicaid Services (搜索) Administrator Mehmet Oz, who spoke to Bloomberg Television ahead of a scheduled keynote address at the Republican midterm convention in Dallas.
Officials have so far announced more than two dozen voluntary agreements with drugmakers, and Oz said "there are more deals in the works." While each agreement is bespoke, companies have generally agreed to lower the prices they charge public programs for medicines and to launch new drugs at prices similar to those paid by other developed markets.
The remarks signal that the voluntary pricing framework is set to expand beyond the deals announced to date, with terms negotiated individually with each participating manufacturer.
Source: Bloomberg Law